HRP20180018T1 - Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja - Google Patents
Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja Download PDFInfo
- Publication number
- HRP20180018T1 HRP20180018T1 HRP20180018TT HRP20180018T HRP20180018T1 HR P20180018 T1 HRP20180018 T1 HR P20180018T1 HR P20180018T T HRP20180018T T HR P20180018TT HR P20180018 T HRP20180018 T HR P20180018T HR P20180018 T1 HRP20180018 T1 HR P20180018T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- compound
- acetylcholinesterase inhibitor
- alzheimer
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US29255910P | 2010-01-06 | 2010-01-06 | |
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
| EP10713790.3A EP2419104B1 (en) | 2009-04-13 | 2010-04-12 | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180018T1 true HRP20180018T1 (hr) | 2018-02-09 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180018TT HRP20180018T1 (hr) | 2009-04-13 | 2010-04-12 | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (https=) |
| EP (1) | EP2419104B1 (https=) |
| JP (1) | JP2012523437A (https=) |
| KR (1) | KR20120017421A (https=) |
| CN (2) | CN102395371A (https=) |
| AU (1) | AU2010236734B2 (https=) |
| BR (1) | BRPI1013777A8 (https=) |
| CA (1) | CA2758321A1 (https=) |
| CY (1) | CY1119800T1 (https=) |
| DK (1) | DK2419104T3 (https=) |
| ES (1) | ES2654930T3 (https=) |
| HR (1) | HRP20180018T1 (https=) |
| HU (1) | HUE038141T2 (https=) |
| IL (1) | IL215660A0 (https=) |
| LT (1) | LT2419104T (https=) |
| MX (1) | MX2011010782A (https=) |
| NO (1) | NO2419104T3 (https=) |
| PL (1) | PL2419104T3 (https=) |
| PT (1) | PT2419104T (https=) |
| RU (1) | RU2569056C2 (https=) |
| SI (1) | SI2419104T1 (https=) |
| SM (1) | SMT201800036T1 (https=) |
| WO (1) | WO2010120695A2 (https=) |
| ZA (1) | ZA201107490B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| LT2889033T (lt) | 2008-11-19 | 2018-07-10 | Forum Pharmaceuticals Inc. | Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ | 老化及び認知症の予防及び／または治療活性を有する乳酸菌 |
| BR112019001145A2 (pt) | 2017-05-24 | 2019-04-30 | H. Lundbeck A/S | combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4 |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| KR20190137936A (ko) | 2017-06-02 | 2019-12-11 | 후지필름 도야마 케미컬 가부시키가이샤 | 뇌 위축 예방 또는 치료제 |
| BR112020000482A2 (pt) | 2017-07-31 | 2020-07-21 | Theravance Biopharma R&D Ip, Llc | métodos de tratamento de sintomas de gastroparesia usando velusetrag |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2133078A1 (en) * | 2000-03-03 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2419104T (pt) | 2018-01-31 |
| RU2011146032A (ru) | 2013-05-20 |
| KR20120017421A (ko) | 2012-02-28 |
| EP2419104B1 (en) | 2017-11-08 |
| IL215660A0 (en) | 2012-01-31 |
| WO2010120695A3 (en) | 2010-12-02 |
| JP2012523437A (ja) | 2012-10-04 |
| US20140057939A1 (en) | 2014-02-27 |
| DK2419104T3 (en) | 2018-02-05 |
| BRPI1013777A8 (pt) | 2017-09-19 |
| US20100261752A1 (en) | 2010-10-14 |
| CA2758321A1 (en) | 2010-10-21 |
| SI2419104T1 (en) | 2018-03-30 |
| AU2010236734A8 (en) | 2012-02-16 |
| NO2419104T3 (https=) | 2018-04-07 |
| CN105832735A (zh) | 2016-08-10 |
| US8404711B2 (en) | 2013-03-26 |
| CN102395371A (zh) | 2012-03-28 |
| MX2011010782A (es) | 2012-01-20 |
| ES2654930T3 (es) | 2018-02-15 |
| LT2419104T (lt) | 2018-02-12 |
| WO2010120695A2 (en) | 2010-10-21 |
| ZA201107490B (en) | 2012-06-27 |
| RU2569056C2 (ru) | 2015-11-20 |
| SMT201800036T1 (it) | 2018-03-08 |
| BRPI1013777A2 (pt) | 2016-04-05 |
| AU2010236734B2 (en) | 2015-06-11 |
| AU2010236734A1 (en) | 2011-11-03 |
| PL2419104T3 (pl) | 2018-04-30 |
| EP2419104A2 (en) | 2012-02-22 |
| HUE038141T2 (hu) | 2018-10-29 |
| CY1119800T1 (el) | 2018-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| Perez-Lloret et al. | Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia | |
| JP2016210798A5 (https=) | ||
| JP2021505575A5 (https=) | ||
| HRP20150711T1 (hr) | Tretiranje kognitivnih poremeä†aja (r)-7-klor-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2012523437A5 (https=) | ||
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| JP2009525343A5 (https=) | ||
| JP2009541443A5 (https=) | ||
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2013518914A5 (https=) | ||
| HRP20100629T1 (hr) | Kristalni oblik spoja kinolinon-karboksamida | |
| JP2016514688A5 (https=) | ||
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2014502996A (ja) | 統合失調症における認知障害の治療 | |
| DE602007014193D1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon | |
| RU2014113941A (ru) | Суспензия для перорального введения | |
| WO2013186311A1 (en) | Extended release formulations | |
| RU2011105463A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА |